



## Phase II study of S-1 on alternate days plus bevacizumab in patients aged 75?years with metastatic colorectal cancer (J-SAVER)

著者 (英)	Toshikazu MORIWAKI, Yoshinori Sakai, Hiroyasu Ishida, Yoshiyuki Yamamoto, Shinji Endo, Hideaki Kuramochi, Mikio Sato, Yukimasa Hatachi, Yoshiaki Bando, Takashi Maeba, Kazuto Ikezawa, Mitsuo Shimada, Kenji Amagai, Masamitsu Morimoto, Kazuma Kobayashi, Akihito Tsuji, Tomohiro Nishina, Ichinosuke Hyodo
journal or publication title	International journal of clinical oncology
volume	24
number	10
page range	1214-1222
year	2019-05
権利	This is a post-peer-review, pre-copyedit version of an article published in International journal of clinical oncology. The final authenticated version is available online at: <a href="http://dx.doi.org/10.1007/s10147-019-01465-3">http://dx.doi.org/10.1007/s10147-019-01465-3</a>
URL	<a href="http://hdl.handle.net/2241/00159455">http://hdl.handle.net/2241/00159455</a>

doi: 10.1007/s10147-019-01465-3

[Click here to view linked References](#)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Original Article

### Title

Phase II study of S-1 on alternate days plus bevacizumab in patients aged  $\geq 75$  years with metastatic colorectal cancer (J-SAVER)

### Authors

Toshikazu Moriwaki<sup>1\*</sup>, Yoshinori Sakai<sup>2</sup>, Hiroyasu Ishida<sup>3</sup>, Yoshiyuki Yamamoto<sup>1</sup>, Shinji Endo<sup>4</sup>, Hideaki Kuramochi<sup>5</sup>, Mikio Sato<sup>6</sup>, Yukimasa Hatachi<sup>7</sup>, Yoshiaki Bando<sup>8</sup>, Takashi Maeba<sup>9</sup>, Kazuto Ikezawa<sup>10</sup>, Mitsuo Shimada<sup>11</sup>, Kenji Amagai<sup>12</sup>, Masamitsu Morimoto<sup>13</sup>, Kazuma Kobayashi<sup>14</sup>, Akihito Tsuji<sup>15</sup>, Tomohiro Nishina<sup>16</sup>, and Ichinosuke Hyodo<sup>1</sup>

### Affiliations

<sup>1</sup>Division of Gastroenterology, Faculty of Medicine, University of Tsukuba, Tsukuba city, Ibaraki, Japan

<sup>2</sup>Department of Gastroenterology, Tsuchiura Kyodo General Hospital, Tsuchiura city, Ibaraki, Japan

<sup>3</sup>Department of Gastroenterology, National Hospital Organization Mito Medical Center, Higashi Ibaraki-gun, Ibaraki, Japan

<sup>4</sup>Division of Gastroenterology and Hepatology, Shinmatsudo Central General Hospital, Matsudo city, Chiba, Japan

<sup>5</sup>Department of Chemotherapy, Tokyo Women's University, Yachiyo Medical Center, Yachiyo city, Chiba, Japan

<sup>6</sup>Department of Gastroenterology and Hepatology, Ryugasaki Saiseikai Hospital, Ryugasaki city, Ibaraki, Japan

<sup>7</sup>Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe city, Hyogo, Japan

<sup>8</sup>Department of Surgery, Tokushima Prefecture Naruto Hospital, Naruto city, Tokushima, Japan

<sup>9</sup>Department of Surgery, Japan Community Health care Organization Ritsurin Hospital, Takamatsu city, Kagawa, Japan

<sup>10</sup>Division of Gastroenterology, Department of Internal Medicine, Tsukuba Memorial Hospital, Tsukuba city, Ibaraki, Japan

<sup>11</sup>Department of Surgery, Tokushima University, Tokushima city, Tokushima, Japan

<sup>12</sup>Division of Gastroenterology and G.I. Oncology, Ibaraki Prefectural Central Hospital and Cancer Center, Kasama city, Ibaraki, Japan

<sup>13</sup>Department of Surgery, Ehime Medical Center, Toon city, Ehime, Japan

1  
2  
3 <sup>14</sup>Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki city,  
4 Nagasaki, Japan  
5

6 <sup>15</sup>Department of Clinical Oncology, Faculty of Medicine, Kagawa University, Kita-gun, Kagawa, Japan  
7

8 <sup>16</sup>Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer  
9 Center, Matsuyama city, Ehime, Japan  
10  
11

12  
13 **Corresponding author**

14 Toshikazu Moriwaki, MD, PhD

15 Division of Gastroenterology, Faculty of Medicine, University of Tsukuba

16 1-1-1, Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.  
17

18 Tel: +81-29-853-3218  
19

20 Fax: +81-29-853-3218  
21

22 E-mail: tmoriwak@gmail.com  
23  
24

25  
26  
27 **Word count:** 2,860 words

28  
29 **Number of tables/figures:** 4/4  
30

31  
32 **Keywords** (five keywords must be listed)

33 bevacizumab, colorectal cancer, elderly, fluoropyrimidine, s-1  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 **Abstract**  
4  
5  
6

7 **Background** Alternate-day administration of S-1 is thought to reduce toxicities. This phase II study  
8  
9  
10 evaluated S-1 on alternate days combined with bevacizumab as first-line treatment for elderly patients  
11  
12  
13  
14 with metastatic colorectal cancer.  
15

16  
17 **Patients and Methods** Eligible patients had histologically proven colorectal adenocarcinoma,  
18  
19  
20  
21 measurable metastatic lesions, age  $\geq 75$  years, Eastern Cooperative Oncology Group performance status  
22  
23  
24  $\leq 1$ , no previous chemotherapy, and refused oxaliplatin- or irinotecan-containing regimens. Patients  
25  
26  
27  
28 received 40 mg, 50 mg, or 60 mg (body surface area  $\leq 1.25$  m<sup>2</sup>,  $>1.25$  to  $\leq 1.50$  m<sup>2</sup>, or  $>1.50$  m<sup>2</sup>,  
29  
30  
31 respectively) of S-1 twice orally on Sunday, Monday, Wednesday, and Friday every week. Bevacizumab  
32  
33  
34  
35 (7.5 mg/kg) was administered every 3 weeks. The primary endpoint was progression-free survival.  
36  
37

38  
39 **Results** Of 54 enrolled patients, 50 patients were evaluated for efficacy and 53 for safety. The median age  
40  
41  
42 was 79 years (range, 75-88 years). The median progression-free survival was 8.1 months (95%  
43  
44  
45 confidence interval, 6.7-9.5 months). The median overall survival was 23.1 months (95% confidence  
46  
47  
48  
49 interval, 17.4-28.8 months). The response rate was 44% (95% confidence interval, 30.2-57.8%), and the  
50  
51  
52  
53 disease control rate was 88% (95% confidence interval, 79.0-97.0%). Grade 3 or higher hematologic,  
54  
55  
56 non-hematologic, and bevacizumab-related adverse events occurred in 9%, 11%, and 25% of patients,  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

respectively. The most common grade 3 and 4 treatment-related adverse events were hypertension (11%),  
nausea (6%), fatigue (6%), anemia (6%), and proteinuria (6%). Only 6 patients discontinued treatment  
due to adverse events.

**Conclusion** S-1 on alternate days combined with bevacizumab showed better tolerability and comparable  
survival compared with the results of similar studies.

1  
2  
3 **Introduction**  
4  
5

6  
7 Colorectal cancer (CRC) is a common cause of cancer-related death worldwide [1,2]. In Japan, more than  
8  
9  
10 70% of mortality occurs in patients over 75 years old. The proportion and number of elderly patients with  
11  
12  
13  
14 metastatic CRC (mCRC) who are treated with chemotherapy is increasing [2].  
15  
16

17           The first-line standard treatment for patients with mCRC is doublet (fluoropyrimidine [FP]  
18  
19  
20 plus oxaliplatin or irinotecan) chemotherapy combined with a molecular targeted agent (bevacizumab,  
21  
22  
23  
24 cetuximab, or panitumumab) [3-5]. However, elderly patients often cannot tolerate this combination  
25  
26  
27  
28 chemotherapy because of emerging adverse events, comorbidity, and decreased organ function.  
29  
30

31  
32 Therefore, FP combined with bevacizumab has been recognized as a favorable treatment for elderly  
33  
34  
35 patients with mCRC [6-8].  
36  
37

38  
39           S-1, an oral FP, showed promising results in two phase II trials for chemo-naïve patients with  
40  
41  
42 mCRC [9,10]. The standard treatment schedule of S-1 was twice daily administration for 4 weeks  
43  
44  
45 followed by 2 weeks' rest. To increase safety, S-1 on alternate days was studied as a new administration  
46  
47  
48  
49 schedule, utilizing the difference in cell cycles between normal gastrointestinal epithelium and tumor  
50  
51  
52  
53 cells: the normal cell cycle is approximately 0.5 to 1.5 days, whereas the tumor cell cycle ranges from 3  
54  
55  
56 to 5 days, and duration of the S-phase, where 5-fluorouracil is most active, is a few days in most cancer  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 cells [11-15]. In a retrospective study, this alternate-day S-1 schedule was studied in 92 patients with  
4  
5  
6  
7 advanced gastric cancer. Grade 2 and higher non-hematologic toxicities were observed in only 3% of the  
8  
9  
10 patients, and the median time to treatment failure and median overall survival (OS) were 6 and 11  
11  
12  
13 months, respectively, which was similar to those in a previous study of the standard S-1 treatment  
14  
15  
16  
17 schedule [16].  
18  
19  
20

21 We herein report a phase II study of S-1 on alternate days combined with bevacizumab as a  
22  
23  
24 first-line treatment in elderly patients with mCRC.  
25  
26  
27  
28  
29  
30

## 31 ***Material and Methods***

### 32 **Study design**

33  
34  
35 This study was designed as a prospective, open-labeled, single-arm, multicenter phase II trial (J-SAVER:  
36  
37  
38  
39 Joint study of S-1 on Alternate days combined with beVacizumab in Elderly patients with metastatic  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

1  
2  
3 by all patients before study entry. The study treatment was started within 14 days from the date of  
4  
5  
6  
7 enrollment. The study protocol was registered at the University Hospital Medical Information Network,  
8  
9  
10 UMIN000010402, on April 2, 2013.  
11  
12  
13  
14  
15  
16

## 17 **Patients**

18  
19  
20  
21 The main inclusion criteria were as follows: pathologically confirmed colorectal adenocarcinoma; age  
22  
23  
24  $\geq 75$  years; Eastern Cooperative Oncology Group performance status (ECOG PS)  $\leq 1$ ; no previous  
25  
26  
27 chemotherapy except for adjuvant chemotherapy with FP completed 6 months or more before enrollment;  
28  
29  
30  
31 presence of measurable lesions as defined by the Response Evaluation Criteria in Solid Tumors  
32  
33  
34 (RECIST) version 1.1; and adequate bone marrow, hepatic, and renal function. The main exclusion  
35  
36  
37  
38 criteria included inability to take oral medication, uncontrolled hypertension, previous radiation therapy  
39  
40  
41  
42 over the pelvic cavity, urine protein  $\geq +2$  with a stick kit for routine urinary analyses, and history of severe  
43  
44  
45 thrombosis. The details of the eligibility criteria have been previously reported [17]. *RAS* mutation was  
46  
47  
48  
49 examined in paraffin-embedded tumor tissues at individual institutions using validated methods approved  
50  
51  
52  
53 by the Japanese Ministry of Labor and Welfare [18,19]. In Japan, *RAS* mutation analysis was performed  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



1  
2  
3 at only *KRAS* exon 2 (codons 12 and 13) until Apr 2015, and expanded to *KRAS/NRAS* exons 2, 3, and 4  
4  
5  
6  
7 thereafter.

### 14 **Treatment schedule**

15  
16  
17 Patients received 40 mg (body surface area [BSA]  $\leq 1.25$  m<sup>2</sup>), 50 mg (BSA  $> 1.25$  to  $\leq 1.50$  m<sup>2</sup>), or 60 mg  
18  
19  
20  
21 (BSA  $> 1.50$  m<sup>2</sup>) of S-1 orally, twice a day, on Sunday, Monday, Wednesday, and Friday every week. The  
22  
23  
24 protocol treatment was repeated until tumor progression, development of severe adverse events, or patient  
25  
26  
27 refusal. Bevacizumab was administered at 7.5 mg/kg every 3 weeks (Fig. 1). S-1 was postponed if the  
28  
29  
30  
31 blood neutrophil count was  $< 1,000/\text{mm}^3$  or the platelet count was  $< 75,000/\text{mm}^3$ . Re-initiation of S-1  
32  
33  
34  
35 required non-hematological toxicities, including infection, diarrhea, oral mucositis, nausea, or vomiting,  
36  
37  
38 to be grade  $\leq 1$ . S-1 was discontinued in cases of serum creatinine level  $\geq 1.2$  mg/dL, serum total bilirubin  
39  
40  
41  
42 level  $\geq 2.5$  mg/dL, serum aspartic aminotransferase (AST) level or serum alanine aminotransferase (ALT)  
43  
44  
45 level  $> 100$  IU ( $> 200$  IU in patients with liver metastasis), and grade 2 or higher diarrhea, mucositis,  
46  
47  
48  
49 nausea, or vomiting. S-1 was re-initiated at a reduced dose if patients recovered from these adverse  
50  
51  
52  
53 events. The dosage of S-1 was reduced by 20% in patients who experienced a neutrophil count  $<$   
54  
55  
56  
57  $500/\text{mm}^3$ , platelet count  $< 50,000/\text{mm}^3$ , serum creatinine level  $\geq 1.5$  mg/dL, serum total bilirubin level  $\geq$   
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 4.0 mg/dL, serum AST or ALT level > 200 IU, or grade 3 or higher diarrhea, mucositis, nausea, or  
4  
5  
6  
7 vomiting. In addition, dose reduction and treatment delay by physician's determination were allowed,  
8  
9  
10 taking into account patient safety.  
11  
12  
13  
14  
15  
16

### 17 **Assessment**

18  
19  
20  
21 Adverse events during treatment were assessed according to the Common Terminology Criteria for  
22  
23  
24 Adverse Events version 4.0. Blood tests included complete blood cell counts, liver and renal function  
25  
26  
27 tests, and tumor markers (carcinoembryonic antigen and carbohydrate antigen 19-9), and the urine test  
28  
29  
30 included a semi-quantitative protein test. Observation, assessment, and blood and urinary tests were  
31  
32  
33 performed every week until the second administration of bevacizumab, and every 3 weeks on the day of  
34  
35  
36 bevacizumab administration thereafter. Tumor assessments were performed according to RECIST version  
37  
38  
39  
40  
41  
42 1.1. Computed tomography or magnetic resonance imaging was performed every 8 weeks for evaluation  
43  
44  
45 of tumors. The relative dose intensity (RDI) of S-1 and bevacizumab were calculated as the actual total  
46  
47  
48 dose divided by the pre-planned total dose during study treatment. A dedicated schedule calendar was  
49  
50  
51  
52  
53 used by patients or family members to record whether the patient orally took S-1.  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 **Statistical analysis**  
4  
5

6  
7 The primary endpoint was progression-free survival (PFS). The secondary endpoints were safety,  
8  
9  
10 response rate, and OS. In a previous phase II study of standard S-1 monotherapy for patients with mCRC,  
11  
12  
13 the median PFS was 5.1 months [9,10]. The median PFS of 5-fluorouracil and leucovorin plus  
14  
15  
16  
17 bevacizumab therapy was 3.7 months longer than that of 5-fluorouracil and leucovorin monotherapy in a  
18  
19  
20  
21 randomized phase II study [6]. Therefore, we set the expected median PFS at 8.5 months and the  
22  
23  
24  
25 minimum efficacy threshold at 5.0 months. The required sample size was calculated as 50 patients, with a  
26  
27  
28 two-sided type I error of 0.10 and a power of  $\geq 80\%$ . As post-hoc analyses, PFS and OS were evaluated  
29  
30  
31 according to *RAS* mutation status: exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4  
32  
33  
34  
35 (codons 117 and 146) of *KRAS* and *NRAS*. PFS was defined as the time from enrollment to disease  
36  
37  
38 progression or death from any cause. OS was defined as the time from enrollment to death from any  
39  
40  
41  
42 cause. The PFS and OS with 95% confidence interval (CI) were estimated using the Kaplan-Meier  
43  
44  
45  
46 method. The response rate with 95% CI was calculated using normal approximation based on the best  
47  
48  
49 response by the investigator. P value of  $< .05$  was considered to indicate statistical significance. All  
50  
51  
52  
53 analyses were performed using SPSS software, version 22.0 (IBM Japan, Tokyo).  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 **Results**  
4  
5

6  
7 **Patients**  
8  
9

10 Fifty-four patients were enrolled from April 2013 to October 2016. Among them, 50 and 53 patients were  
11  
12  
13  
14 evaluated for efficacy and safety, respectively. The flow chart of patient selection is shown in Fig. 2.  
15

16  
17 The median patient age was 79 years (range, 75-88 years) (Table 1). The ECOG PS was 0 in  
18  
19  
20  
21 28 patients (56%) and 1 in 22 patients (44%). Primary tumors were located in the cecum, ascending  
22  
23  
24 colon, and transverse colon in 15 patients (30%) (right side), and in the descending colon, sigmoid colon,  
25  
26  
27 and rectum in 35 patients (70%) (left side). Half of the patients had one metastatic site. The tumor *RAS*  
28  
29  
30  
31 mutation status was examined in 44 patients (21 wild-type and 23 mutant *RAS*).  
32  
33  
34  
35  
36  
37  
38

39 **Efficacy**  
40  
41

42 The median follow-up times for PFS and OS were 34.5 and 44.9 months, respectively. PFS events  
43  
44  
45 occurred in 40 patients (80%). The median PFS was 8.1 months (95% CI, 6.7-9.5 months) (Fig. 3a).  
46  
47

48  
49 Thirty-nine patients (78%) died. The median OS was 23.1 months (95% CI, 17.4-28.8 months) (Fig. 3b).  
50  
51

52  
53 One patient showed complete response, and 21 had partial responses. The response rate was 44% (95%  
54  
55  
56 CI, 30.2-57.8%), and the disease control rate was 88% (95% CI, 79.0-97.0%). Waterfall plots of the best  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 responses are shown in Fig. 4. Tumor shrinkage was observed in 37 patients (74%). Four patients showed  
4  
5  
6  
7 100% tumor regression, but 2 patients with partial response had non-measurable lesions and 1 patient  
8  
9  
10 with stable disease had a new lesion when the measurable lesions had disappeared.  
11  
12

13  
14 In post-hoc survival analyses according to *RAS* mutation status, the median PFS were 7.9  
15  
16  
17 months (95% CI, 7.1-8.7 months) for patients with wild-type *RAS* and 7.8 months (95% CI, 6.6-8.9  
18  
19  
20 months) for those with mutant *RAS* ( $P = 0.80$ ). The median OS were 24.2 months (95% CI, 17.3-31.0  
21  
22  
23 months) for patients with wild-type *RAS* and 23.8 months (95% CI, 8.9-38.7 months) for those with  
24  
25  
26  
27 mutant *RAS* ( $P = 0.80$ ).  
28  
29  
30  
31  
32  
33  
34

### 35 **Safety**

36  
37  
38 The adverse events are summarized in Table 2. Grade 3 or higher hematologic, non-hematologic, and  
39  
40  
41 bevacizumab-related adverse events were observed in 5 (9%), 6 (11%), and 13 (25%) patients,  
42  
43  
44  
45 respectively. The most common grade 3 and 4 treatment-related adverse events were hypertension (11%),  
46  
47  
48  
49 anemia (6%), nausea (6%), fatigue (6%), and proteinuria (6%). Treatment-related death caused by  
50  
51  
52  
53 cerebral infarction was observed in one patient. The patient experienced several grade 2 non-hematologic  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 toxicities, and the dose of S-1 was reduced to 60% of the initial dose. He developed cerebral infarction  
4  
5  
6  
7 after 13 doses of bevacizumab and died 12 months after the start of the study treatment.  
8  
9

10 The median duration of treatment was 7.8 months (range, 0.5-31.5 months). The median  
11  
12 cumulative dose of S-1 was 13,060 mg (range, 280-54,250 mg) and that of bevacizumab was 3,980 mg  
13  
14 (range, 270-24,910 mg). Seventeen patients (32%) required dose reduction or treatment delay of S-1, and  
15  
16  
17  
18  
19  
20  
21 14 patients (26%) required treatment delay of bevacizumab. The median RDI was 92% (range, 20-100%)  
22  
23  
24 for S-1 and 89% (range, 34-100%) for bevacizumab. The median RDI according to the original S-1  
25  
26  
27  
28 treatment schedule was 79% (range, 18-84%).  
29  
30

### 31 **Subsequent treatments**

32  
33  
34

35 Among the patients who received study treatment ( $n = 53$ ), discontinuation of the study  
36  
37  
38 treatment was reported in 50 patients (94%), and the reason for discontinuation was disease progression  
39  
40  
41  
42 in 40 patients (75%), adverse events in 6 patients (11%) (1 patient each: grade 2 anorexia, grade 2  
43  
44  
45 anorexia and fatigue, grade 3 anorexia, grade 3 wound dehiscence, grade 3 colonic perforation, and grade  
46  
47  
48  
49 5 cerebral infarction), withdrawal of consent in 1 patient, and other in 3 patients (1 patient each: sepsis  
50  
51  
52  
53 due to aspiration pneumonia, dementia, and unknown) (Table 3). After discontinuation of the study  
54  
55  
56 treatment, 14 patients (26%) received best supportive care alone, and 33 patients (62%) were treated with  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 any chemotherapy, including oxaliplatin- and irinotecan-containing therapy ( $n = 14$  and  $8$ , respectively).  
4  
5

6  
7 In 22 patients who received oxaliplatin- or irinotecan- containing therapy, the median age was 78 years  
8  
9

10 (range, 75-86 years), and 14 patients (64%) had an ECOG PS of 0. No complete response was observed,  
11  
12

13 and 10 patients achieved partial response (45%). The incidences of grade 3 or higher hematologic-, non-  
14  
15

16 hematologic-, and bevacizumab-related toxicities were 5%, 9%, and 14%, respectively. The median RDIs  
17  
18

19 were 95% (range, 46-98%) for S-1 and 93% (34-100%) for bevacizumab.  
20  
21  
22  
23  
24  
25  
26  
27

## 28 **Discussion**

29  
30

31 We studied S-1 administration on alternate days combined with bevacizumab as first-line treatment for  
32  
33

34 elderly ( $\geq 75$  years) patients with mCRC in a multicenter phase II trial, and showed modest activity and  
35  
36

37 well-tolerated toxicities, while keeping dose intensities of S-1 and bevacizumab as high as approximately  
38  
39

40  
41  
42 90%.  
43  
44  
45

46 The main results reported in similar studies of elderly patients with mCRC are summarized in  
47  
48

49 Table 4. The PFS in our study was comparable to those in previous studies of other FPs combined with  
50  
51

52 bevacizumab [7,20-22]. The dose intensity of S-1 on alternate days corresponded with approximately  
53  
54  
55

56 86% of the standard daily S-1 dose, and the actual median dose in alternate-day S-1 administration was  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 79% of the standard dose in the present study. In general, FP plus bevacizumab has been reported to be  
4  
5  
6  
7 well tolerated in elderly patients. However, the incidence of grade 3 or higher toxicities was reported as  
8  
9  
10 30% in two studies [7,23]. Even in other studies in which grade 3 or higher toxicities were observed in  
11  
12  
13 less than 10% of patients, treatment was discontinued due to relatively mild to moderate toxicities in  
14  
15  
16 approximately 30% of patients [20,22]. In contrast, the incidence of grade 3 or higher toxicities in our  
17  
18  
19 study was low, as expected, and only 11% of patients discontinued treatment due to toxicities. In  
20  
21  
22  
23  
24 addition, incidences of lacrimal disorder and skin disorder, including hand-foot skin reaction, were lower  
25  
26  
27  
28 than those in previous studies in elderly patients [7,22]. This suggests that an alternate-day S-1 schedule  
29  
30  
31 had better tolerability than previously reported FP plus bevacizumab regimens.  
32  
33

34  
35 Recently, two randomized phase II studies of alternate-day S-1 therapy were reported in  
36  
37  
38 advanced gastric and pancreatic cancers [24,25]. This regimen was inferior in efficacy to the standard  
39  
40  
41 daily S-1 regimen, although adverse events were mild. One plausible reason for these negative results is  
42  
43  
44 the insufficient anti-tumor activity of S-1 due to underdosing in the alternate-day schedule. Nevertheless,  
45  
46  
47 these results in advanced gastric and pancreatic cancer do not undermine our favorable results in elderly  
48  
49  
50 mCRC patients. These studies included younger patients who could have tolerated the standard daily S-1  
51  
52  
53 regimen, and elderly patients accounted for less than half of the population. Starting with a reduced dose  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



1  
2  
3 of FP was often adopted in previous studies for elderly patients with mCRC [6,20,21,23]. In a phase II  
4  
5  
6  
7 study, aggressive dose modification of capecitabine plus bevacizumab provided rather favorable results in  
8  
9  
10 elderly mCRC patients [26]. In the FOCUS2 trial for elderly/frail patients in which FP alone or FP  
11  
12  
13 combined with oxaliplatin was started at a reduced dose, only 37% of patients could tolerated a dose  
14  
15  
16 increased to the standard level. In contrast, doublet regimens have been reported to demonstrate  
17  
18  
19 promising activity and tolerability in elderly patients with mCRC [23,27-30]. Although doublet regimens  
20  
21  
22 should be considered first for elderly patients, not all elderly patients can continue those treatments  
23  
24  
25 because of toxicities, and a considerable number of patients actually refuse them to avoid treatment-  
26  
27  
28 related toxicities. Our regimen may be a good option as an introductory treatment for such patients.  
29  
30  
31  
32  
33

34  
35 Our study suggested that *RAS* mutation had no impact on PFS in patients administered FP  
36  
37  
38 plus bevacizumab, similar to the results of a previous report [31]. Anti-epidermal growth factor receptor  
39  
40  
41 (EGFR) antibody-containing therapy is recommended for mCRC patients with wild-type *RAS*, and  
42  
43  
44 bevacizumab-containing therapy is an optional treatment. In a previous report, the median PFS was 6.4  
45  
46  
47 months in elderly patients with wild-type *KRAS* and 8.4 months in those with wild-type *KRAS/NRAS* [32-  
48  
49  
50  
51  
52  
53 34]. The median PFS in our patients with wild-type *KRAS* or *KRAS/NRAS* was similar to these previously  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 reported values. If elderly patients want to avoid anti-EGFR antibody-related skin toxicities, our regimen  
4  
5  
6  
7 would be a good substitute.  
8  
9

10  
11 Elderly patients are extremely diverse. Therefore, the present study had several limitations.

12  
13 The tolerability of chemotherapy for elderly patients is often associated with polypharmacy, comorbidity,  
14  
15  
16  
17 renal function, psychological state, and family support [35,36]. We could not assess these important  
18  
19  
20  
21 factors; however, they are very difficult to investigate in all clinical trials. Geriatric function assessment  
22  
23  
24 was lacking in our study. Various tools have been attempted for geriatric assessment in oncology trials,  
25  
26  
27  
28 but a convenient, useful, and validated tool has not yet been established [35,36]. That the adherence rate  
29  
30  
31 of oral anti-cancer drugs is lower than that of intravenous anti-cancer drugs also needs to be considered  
32  
33  
34 [37]. In order to maintain the dose intensity of S-1 in this study, we asked the patients and their family  
35  
36  
37  
38 members to record the day and dose of orally administered S-1 using a dedicated schedule calendar, and  
39  
40  
41  
42 we checked the adherence.  
43  
44

45  
46 In conclusion, alternate-day S-1 combined with bevacizumab was well tolerated and  
47  
48  
49 maintained activity in elderly patients ( $\geq 75$  years old) with mCRC and might be recommended as an  
50  
51  
52  
53 optional treatment. Further studies are needed to evaluate the influence of different FP toxicities on  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

patients' quality of life and to find the optimal treatment for individual patients based on geriatric  
assessment.

1  
2  
3 **Acknowledgements**  
4  
5  
6

7 We are grateful to Kentaro Yamazaki, Takako E. Nakajima, and Takehiro Oikawa for their important  
8  
9  
10 contributions to this study as part of the Data and Safety Monitoring Committee and Miss Mizuki Aida  
11  
12  
13 for data management. The participating investigators are as follows: T. Masuishi and T. Eto (Tsuchiura  
14  
15  
16  
17  
18 Kyodo General Hospital); S. Yoshida, Y. Ito, and M. Shimoyamada (National Hospital Organization  
19  
20  
21 Mito Medical Center); T. Murashita (Ryugasaki Saiseikai Hospital); H. Satake (Kobe City Medical  
22  
23  
24  
25 Center General Hospital); M. Chikakiyo (Tokushima Prefecture Naruto Hospital); T. Fujita and S. Mori  
26  
27  
28 (JCHO Ritsurin Hospital), A. Soeda and M. Kobayashi (Tsukuba Memorial Hospital), J. Higashijima and  
29  
30  
31 T. Nakao (Tokushima University); M. Inukai and Y. Suzuki (Kagawa University), M. Goto (Ibaraki  
32  
33  
34  
35 Prefectural Central Hospital and Cancer Center). This work is supported by the NPO Tsukuba Cancer  
36  
37  
38  
39 Clinical Trial Group. We would like to thank Editage ([www.editage.jp](http://www.editage.jp)) for English language editing.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Compliance with ethical standards**

**Conflict of Interest** MS received a research funding from Chugai, Taiho, CSL Behring, MSD, Astellas, AbbVie, Eisai, Ono, TSUMURA, Coviklen Japan, Johnson&Johnson, Takeda, Novartis, Bayer Yakuin, and Merck Serono; KA received research funding from Taiho, Hisamitsu, and MSD; AT received honoraria from Chugai and Taiho; TN received research funding from Taiho; IH received honoraria and research funding from Taiho and Chugai. All other authors declare no potential conflicts of interest.

## References

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 136 **5**:E359-386. <https://www.ncbi.nlm.nih.gov/pubmed/25220842>
2. Matsuda A, Matsuda T, Shibata A, Katanoda K, Sobue T (2013) Cancer incidence and incidence rates in Japan in 2007: a study of 21 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. *Jpn J Clin Oncol* 43 **3**:328-336. <https://www.ncbi.nlm.nih.gov/pubmed/23296772>
3. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. *J Clin Oncol* 26 **12**:2013-2019. <https://www.ncbi.nlm.nih.gov/pubmed/18421054>
4. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *N Engl J Med* 360 **14**:1408-1417. <https://www.ncbi.nlm.nih.gov/pubmed/19339720>
5. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. *J Clin Oncol* 28 **31**:4697-4705. <https://www.ncbi.nlm.nih.gov/pubmed/20921465>
6. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E (2005) Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. *J Clin Oncol* 23 **16**:3706-3712. <https://www.ncbi.nlm.nih.gov/pubmed/15867200>
7. Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J (2013) Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. *Lancet Oncol* 14 **11**:1077-1085. <https://www.ncbi.nlm.nih.gov/pubmed/24028813>
8. Price TJ, Zannino D, Wilson K, Simes RJ, Cassidy J (2012) Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C. *Ann Oncol* 23 **6**:1531-1536. <https://www.ncbi.nlm.nih.gov/pubmed/22039086>
9. Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N (2000) Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative

- 1  
2  
3 Colorectal Carcinoma Study Group. *Br J Cancer* 83 **2**:141-145.  
4 <https://www.ncbi.nlm.nih.gov/pubmed/10901361>  
5
- 6 10. Shirao K, Ohtsu A, Takada H, Mitachi Y, Hirakawa K (2004) Phase II study of oral S-1 for treatment  
7 of metastatic colorectal carcinoma. *Cancer* 100 **11**:2355-2361.  
8 <https://www.ncbi.nlm.nih.gov/pubmed/15160338>  
9
- 10 11. Shirasaka T (2009) Development history and concept of an oral anticancer agent S-1 (TS-1): its  
11 clinical usefulness and future vistas. *Jpn J Clin Oncol* 39 **1**:2-15.  
12 <https://www.ncbi.nlm.nih.gov/pubmed/19052037>  
13
- 14 12. Cronkite EP, Bond VP, Fliedner TM, Rubini JR (1959) The use of tritiated thymidine in the study of  
15 DNS synthesis and cell turnover in hemopoietic tissues. *Lab Invest* 8 **1**:263-275; discussion 276-267.  
16 <https://www.ncbi.nlm.nih.gov/pubmed/13621625>  
17
- 18 13. Lipkin M, Sherlock P, Bell B (1963) Cell Proliferation Kinetics in the Gastrointestinal Tract of Man.  
19 ii. Cell Renewal in Stomach, Ileum, Colon, and Rectum. *Gastroenterology* 45:721-729.  
20 <https://www.ncbi.nlm.nih.gov/pubmed/14134007>  
21
- 22 14. Clarkson B, Ota K, Ohkita T, O'Connor A (1965) Kinetics of proliferation of cancer cells in  
23 neoplastic effusions in man. *Cancer* 18 **10**:1189-1213.  
24 <https://www.ncbi.nlm.nih.gov/pubmed/5890960>  
25
- 26 15. Arai W, Hosoya Y, Haruta H, Kurashina K, Saito S (2008) Comparison of alternate-day versus  
27 consecutive-day treatment with S-1: assessment of tumor growth inhibition and toxicity reduction in  
28 gastric cancer cell lines in vitro and in vivo. *Int J Clin Oncol* 13 **6**:515-520.  
29 <https://www.ncbi.nlm.nih.gov/pubmed/19093179>  
30
- 31 16. Arai W, Hosoya Y, Hyodo M, Yokoyama T, Hirashima Y (2004) Alternate-day oral therapy with TS-  
32 1 for advanced gastric cancer. *Int J Clin Oncol* 9 **3**:143-148.  
33 <https://www.ncbi.nlm.nih.gov/pubmed/15221596>  
34
- 35 17. Moriwaki T, Eto T, Tsuji A, Kakinoki N, Shimada M (2017) Rationale and Study Protocol of the J-  
36 SAVER Study: A Phase II Study of S-1 on Alternate Days Combined with Bevacizumab in Patients  
37 Aged  $\geq 75$  Years with Metastatic Colorectal Cancer. *Journal of Cancer Therapy* 08 **11**:1040-1048.  
38 [http://file.scirp.org/Html/9-8902654\\_80659.htm](http://file.scirp.org/Html/9-8902654_80659.htm)  
39
- 40 18. Yoshino T, Muro K, Yamaguchi K, Nishina T, Denda T (2015) Clinical Validation of a Multiplex Kit  
41 for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEY Testing) Prospective,  
42 Multicenter Study. *EBioMedicine* 2 **4**:317-323. <https://www.ncbi.nlm.nih.gov/pubmed/26137573>  
43
- 44 19. Alqahtani QM, Crowley A, Rapp S, Cushman-Vokoun AM (2016) QIAGEN Therascreen KRAS  
45 RQ Assay, QIAGEN KRAS Pyro Assay, and Dideoxy Sequencing for Clinical Laboratory Analysis  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- of KRAS Mutations in Tumor Specimens. *Lab Med* 47 1:30-38.  
<https://www.ncbi.nlm.nih.gov/pubmed/26732779>
20. Nishina T, Moriwaki T, Shimada M, Higashijima J, Sakai Y (2016) Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged  $\geq$  75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLUE] Study). *Clin Colorectal Cancer* 15 3:236-242.  
<https://www.ncbi.nlm.nih.gov/pubmed/26778644>
21. Mizushima T, Tamagawa H, Matsuda C, Murata K, Fukunaga M (2015) Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer. *Oncology* 89 3:152-158.  
<https://www.ncbi.nlm.nih.gov/pubmed/25967649>
22. Yoshida M, Muro K, Tsuji A, Hamamoto Y, Yoshino T (2015) Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial). *Eur J Cancer* 51 8:935-941. <https://www.ncbi.nlm.nih.gov/pubmed/25837882>
23. Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE (2011) Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. *Lancet* 377 9779:1749-1759.  
<https://www.ncbi.nlm.nih.gov/pubmed/21570111>
24. Tanaka H, Kanda M, Morita S, Taguri M, Nishikawa K (2017) Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003). *Int J Clin Oncol* 22 6:1052-1059. <https://www.ncbi.nlm.nih.gov/pubmed/28667408>
25. Yamaue H, Shimizu A, Hagiwara Y, Sho M, Yanagimoto H (2017) Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer. *Cancer Chemother Pharmacol* 79 4:813-823. <https://www.ncbi.nlm.nih.gov/pubmed/28251282>
26. Naeim A, Ward PR, Wang HJ, Dichmann R, Liem AK (2013) A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer. *J Geriatr Oncol* 4 4:302-309. <https://www.ncbi.nlm.nih.gov/pubmed/24472472>
27. Rosati G, Avallone A, Aprile G, Butera A, Reggiardo G (2013) XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study. *Cancer Chemother Pharmacol* 71 1:257-264.  
<https://www.ncbi.nlm.nih.gov/pubmed/23100174>



- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
28. Feliu J, Salud A, Safont MJ, Garcia-Giron C, Aparicio J (2014) First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study. *Br J Cancer* 111 2:241-248. <https://www.ncbi.nlm.nih.gov/pubmed/24946000>
  29. Munemoto Y, Kanda M, Ishibashi K, Hata T, Kobayashi M (2015) Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer. *BMC Cancer* 15:786. <https://www.ncbi.nlm.nih.gov/pubmed/26497654>
  30. Vamvakas L, Matikas A, Karampeazis A, Hatzidaki D, Kakolyris S (2014) Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG). *BMC Cancer* 14:277. <https://www.ncbi.nlm.nih.gov/pubmed/24755296>
  31. Price TJ, Hardingham JE, Lee CK, Weickhardt A, Townsend AR (2011) Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. *J Clin Oncol* 29 19:2675-2682. <https://www.ncbi.nlm.nih.gov/pubmed/21646616>
  32. Sastre J, Gravalos C, Rivera F, Massuti B, Valladares-Ayerbes M (2012) First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study. *Oncologist* 17 3:339-345. <https://www.ncbi.nlm.nih.gov/pubmed/22363067>
  33. Sastre J, Massuti B, Pulido G, Guillen-Ponce C, Benavides M (2015) First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours. *Eur J Cancer* 51 11:1371-1380. <https://www.ncbi.nlm.nih.gov/pubmed/25963019>
  34. Pietrantonio F, Cremolini C, Aprile G, Lonardi S, Orlandi A (2015) Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. *Oncologist* 20 11:1261-1265. <https://www.ncbi.nlm.nih.gov/pubmed/26446234>
  35. Extermann M, Hurria A (2007) Comprehensive geriatric assessment for older patients with cancer. *J Clin Oncol* 25 14:1824-1831. <https://www.ncbi.nlm.nih.gov/pubmed/17488980>
  36. Li D, Soto-Perez-de-Celis E, Hurria A (2017) Geriatric Assessment and Tools for Predicting Treatment Toxicity in Older Adults With Cancer. *Cancer J* 23 4:206-210. <https://www.ncbi.nlm.nih.gov/pubmed/28731942>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

37. Seal BS, Anderson S, Shermock KM (2016) Factors Associated with Adherence Rates for Oral and Intravenous Anticancer Therapy in Commercially Insured Patients with Metastatic Colon Cancer. J Manag Care Spec Pharm 22 3:227-235. <https://www.ncbi.nlm.nih.gov/pubmed/27003552>

1  
2  
3 **Figure captions**  
4  
5

6  
7 **Fig. 1** Treatment schedule. BSA, body-surface area.  
8  
9

10 **Fig. 2** Flow diagram indicating patient enrollment.  
11  
12

13 **Fig. 3** Kaplan-Meier curves of progression-free survival (a) and overall survival (b). The median  
14 progression-free survival was 8.1 months (95% CI, 6.7-9.5). The median overall survival was 23.1  
15 months (95% CI, 17.4-28.8). CI, confidence interval.  
16  
17  
18  
19  
20  
21  
22  
23

24 **Fig. 4** Waterfall plots according to the best response. CR, complete response; PD, progressive disease;  
25  
26  
27 PR, partial response; SD, stable disease.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Table 1** Patient characteristics

<b>Characteristics</b>	<b>n = 50</b>	<b>%</b>
Age (years)		
Median (range)	79 (75-88)	
Gender		
Male	25	50
Female	25	50
ECOG performance status		
0	28	56
1	22	44
Histology		
Well differentiated adenocarcinoma	10	20
Moderate differentiated adenocarcinoma	35	70
Poorly differentiated adenocarcinoma	2	4
Mucinous adenocarcinoma	3	6
Primary tumor site		
Cecum/ascending colon/transverse colon	15	30
Descending colon/sigmoid colon/rectum	35	70
Metastasis		
Synchronous	33	66
Metachronous	17	34
Primary therapy		
Resection of primary tumor	39	78
Adjuvant chemotherapy	5	10
Metastatic organ site		
Liver	28	56
Lung	19	38
Peritoneum	15	30
Lymph node	11	22
Others	12	24
Number of metastatic organ site		
1	26	52
2	17	34
≥3	7	14
<i>RAS</i> status		
<i>KRAS</i> exon 2 <sup>+</sup> wild-type	9	18
<i>KRAS/NRAS</i> <sup>‡</sup> wild-type	12	24

<i>KRAS/NRAS</i> <sup>‡</sup> mutant-type	23	46
Unkown	6	12

---

<sup>†</sup>codon 12 and 13. <sup>‡</sup>exon 2 (codon 12 and 13), exon 3 (codon 59 and 61), and exon 4 (117 and 146) of *KRAS* and *NRAS*

*ECOG PS* Eastern Cooperative Oncology Group Performance Status

**Table 2** Treatment-related adverse events

Toxicities	Toxicity grade <sup>†</sup> (n = 53)						
	0	1	2	3	4	Any (%)	≥3 (%)
Hematologic							
Any	21	15	12	5	0	60	9
Neutropenia	43	3	5	2	0	19	4
Anemia	25	14	7	3	0	53	6
Thrombocytopenia	29	10	4	0	0	45	0
Non-hematologic							
Any	14	17	16	6	0	74	11
Oral mucositis	39	10	4	0	0	26	0
Nausea	34	10	6	3	-	36	6
Vomiting	47	3	3	0	0	11	0
Diarrhea	42	6	3	2	0	21	4
Fatigue	31	14	5	3	-	42	6
Anorexia	44	3	5	1	0	17	2
Lacrimal disorder	47	4	2	0	0	11	0
Skin disorder	38	13	2	0	0	28	0
Febrile neutropenia	53	-	-	0	0	0	0
Bevacizumab-related							
Any	15	11	14	11	2 <sup>‡</sup>	72	25
Hypertension	33	6	8	6	0	38	11
Bleeding	37	13	1	2	0	30	4
Proteinuria	27	8	15	3	0	49	6
Thrombosis	51	0	1	0	1 <sup>‡</sup>	4	2
Wound dehiscence	52	0	0	1	0	2	2
Colonic perforation	52	0	0	0	1	2	2

-: Grade is not available

<sup>†</sup>Toxicity grade was done according to the National Cancer Institute Common Terminology Criteria version 4.0

‡Treatment related death was observed in one patient

**Table 3** Subsequent treatment

	<b>(n = 53)</b>	<b>%</b>
Study treatment continued	3	6
Study treatment discontinued	50	94
Best supportive care	14	26
Any chemotherapies	32	60
Oxaliplatin-containing	14	26
Irinotecan-containing	8	15
Fluoropyrimidine alone or with bevacizumab	7	13
Anti-EGFR antibody alone	1	2
Trifluridine/tipiracil	2	4
Other	1	2
Radiotherapy	2	4
Treatment-related death	1	2

*EGFR* epidermal growth factor receptor.




**Table 4** Summary of studies of oral fluoropyrimidine with bevacizumab as first-line therapy for elderly patients with metastatic colorectal cancer


	J-BLUE <sup>18</sup>	Osaka <sup>19</sup>	BASIC <sup>20</sup>	AVEX <sup>7</sup>	Present study
Trial phase	II	II	II	III	II
FP combined with bevacizumab	UFT/LV	UFT/LV	S-1	Capecitabine	Alternate-day S-1
Schedule of FP	300 mg/m <sup>2</sup> /day for 3 weeks on, 1 week off	300 mg/m <sup>2</sup> /day for 3 weeks on, 1 week off	80 mg/m <sup>2</sup> /day for 4 weeks on, 2 weeks off	2,000 mg/m <sup>2</sup> /day for 2 weeks on, 1 week off	80 mg/m <sup>2</sup> /day on Sun, Mon, Wed, and Fri
Number of patients <sup>†</sup>	52	40	56	134	50
Age (years), median (range)	80 (75-87)	81 (75-90)	75 (66-85)	76 (70-87)	79 (75-88)
ECOG PS ≥1, %	27	13	50	48	44
Median PFS, month	8.2	8.9	9.9	9.1	8.1
Median OS, month	23.0	21.7	25.0	20.7	21.0
Any AEs grade ≥3, %	29	NR	NR	40	36
Discontinuation due to AEs <sup>‡</sup> , %	25	NR	32	17	11


<sup>†</sup>Efficacy analysis population

<sup>‡</sup>Of the number of patients who received study treatment

*AEs* adverse events *ECOG PS* Eastern Cooperative Oncology Group Performance Status *FP* fluoropyrimidine *LV* oral leucovorin *NR* not reported *OS* overall survival *PFS* progression-free survival *UFT* Uracil-Tegafur










Fig 4 Waterfall plots to the best response

[Click here to access/download;Figure;Fig 4 waterfall plots to the best response.tiff](#)

